Open AccessStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors
Author(s) -
Yong-Jia Hao,
Jiankun Lyu,
Rong Qu,
Deheng Sun,
Zhenjiang Zhao,
Zhuo Chen,
Jian Ding,
Hua Xie,
Yufang Xu,
Honglin Li
Publication year - 2017
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-017-04184-9
Subject(s) - t790m , epidermal growth factor receptor , mutant , egfr inhibitors , in vivo , cancer research , cell culture , chemistry , pharmacology , receptor , biology , gefitinib , biochemistry , gene , genetics
Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9 ), and designed a series of C4-alkyl-1,4-dihydro-2 H -pyrimido[4,5- d ][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors. Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFR L858R/T790M (H1975 cell lines) over EGFR WT (A431 cell lines). The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFR L858R/T790M . These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.